高胆固醇血症治疗市场－全球产业规模、份额、趋势、机会和预测，按疾病类型、治疗类型、最终用户、地区和竞争细分，2020 年至 2030 年

2024 年全球高胆固醇血症治疗市场价值为 213.8 亿美元，预计到 2030 年将达到 338.1 亿美元，预测期内年复合成长率(CAGR) 为 7.91%。这种增长轨迹很大程度上归因于心血管疾病盛行率的上升以及全球被诊断为胆固醇水平升高的人口的增加。

不健康的饮食习惯、久坐的生活方式和遗传倾向是导致高胆固醇血症发病率不断上升的关键因素。这些情况正在推动对有效治疗方案的需求。大众对低密度脂蛋白 (LDL) 胆固醇升高所带来的健康风险（如心臟病发作、中风和周边动脉疾病）的认识不断提高，凸显了早期诊断和及时治疗介入的重要性。

此外，公共和私营部门医疗保健计划的大力支持也促进了筛检计划的扩大和对常规胆固醇检测的更大倡导。这些项目鼓励个人主动寻求医疗指导和适当的治疗方案。

市场驱动因素

高胆固醇血症盛行率上升

市场挑战

治疗费用高昂

市场趋势

药物研究的进展

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球高胆固醇血症治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依疾病类型（遗传性高胆固醇血症、后天性高胆固醇血症）
  • 依治疗类型（他汀类药物、PCSK9 抑制剂、依折麦布、胆汁酸螯合剂、烟碱酸、贝培酸等）
  • 按最终使用者（医院、心臟专科中心等）
  • 按公司分类（2024）
  • 按地区
• 市场地图

第六章：北美高胆固醇血症治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第七章：欧洲高胆固醇血症治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太高胆固醇血症治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第九章：南美洲高胆固醇血症治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东和非洲高胆固醇血症治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第 13 章： 大环境分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章：竞争格局

• Amgen Inc
• Amryt Pharma plc
• AstraZeneca Plc.
• Regeneron Pharmaceuticals, Inc.
• Novartis Pharmaceuticals Corporation
• Teva Pharmaceutical Industries Ltd.
• Cipher Pharmaceuticals Inc.
• Pfizer Inc.
• Merck & Co., Inc.
• Sun Pharmaceutical Industries Limited

第 16 章：策略建议

第17章调查会社について・免责事项

Global Hypercholesterolemia treatment market was valued at USD 21.38 billion in 2024 and is projected to reach USD 33.81 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.91% during the forecast period. This growth trajectory is largely attributed to the increasing prevalence of cardiovascular diseases and a rising global population diagnosed with elevated cholesterol levels.

Unhealthy dietary habits, sedentary lifestyles, and genetic predispositions are among the key factors contributing to the growing incidence of hypercholesterolemia. These conditions are fueling demand for effective treatment solutions. Increased public awareness regarding the health risks associated with elevated LDL (low-density lipoprotein) cholesterol-such as heart attacks, strokes, and peripheral arterial disease-has underscored the importance of early diagnosis and prompt therapeutic intervention.

Furthermore, robust support from both public and private sector healthcare initiatives has led to expanded screening programs and greater advocacy for routine cholesterol testing. These programs are encouraging individuals to proactively seek medical guidance and appropriate treatment options.

Market Drivers

Rising Prevalence of Hypercholesterolemia

The global rise in hypercholesterolemia cases is strongly linked to evolving lifestyle and dietary trends. Sedentary routines combined with high intake of saturated fats and processed foods have significantly increased the number of individuals with high cholesterol levels. According to the World Health Organization (WHO), in 2008, the global prevalence of raised total cholesterol among adults stood at 39% (37% among males and 40% among females), highlighting the widespread nature of this health issue.

Additionally, the global population is aging at a rapid pace. The United Nations Department of Economic and Social Affairs projects that the population aged 65 and older will reach 1.5 billion by 2050, up from 703 million in 2019. Aging is associated with a decline in the body's efficiency in metabolizing and regulating cholesterol, thereby increasing vulnerability to hypercholesterolemia.

Market Challenges

High Cost of Treatment

One of the most pressing challenges in the hypercholesterolemia treatment market is the high cost of therapies, which can hinder access to care and negatively impact patient outcomes. As a chronic condition, hypercholesterolemia typically requires long-term treatment, adding to the financial burden on both patients and healthcare systems.

Although several treatment options are available-including statins and newer agents such as PCSK9 inhibitors-their cost can be prohibitively high, especially for patients without comprehensive insurance coverage. This often leads to delayed treatment initiation, suboptimal adherence, and increased risk of cardiovascular complications.

The economic burden is further compounded by healthcare disparities, particularly among low-income populations who may struggle to afford necessary medications and follow-up care. Consequently, these financial obstacles contribute to unequal access to care and exacerbate existing public health challenges.

Healthcare systems and insurers also face strain from the high cost of providing widespread access to advanced cholesterol-lowering therapies. This pressure may result in limitations on coverage, reduced treatment availability, and compromised quality of care.

Market Trends

Advancements in Pharmaceutical Research

Innovations in pharmaceutical research are significantly advancing the global hypercholesterolemia treatment landscape. While statins have long served as the standard of care, recent developments have introduced novel therapeutic options that are reshaping the market.

Among the most notable innovations is the emergence of PCSK9 inhibitors, which provide an alternative mechanism for lowering LDL cholesterol, particularly in patients who do not respond adequately to statin therapy. These biologics target a specific protein involved in cholesterol regulation, offering enhanced efficacy for certain patient groups.

Ongoing research is also yielding drugs with improved safety profiles and fewer side effects, addressing concerns associated with traditional therapies such as muscle pain. These developments have led to a broader range of treatment options, improving patient compliance and clinical outcomes.

Key Market Players

• Amgen Inc
• Amryt Pharma plc
• AstraZeneca Plc.
• Regeneron Pharmaceuticals, Inc.
• Novartis Pharmaceuticals Corporation
• Teva Pharmaceutical Industries Ltd.
• Cipher Pharmaceuticals Inc.
• Pfizer Inc.
• Merck & Co., Inc.
• Sun Pharmaceutical Industries Limited

Report Scope:

In this report, the Global Hypercholesterolemia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hypercholesterolemia Treatment Market, By Disease Type:

• Genetic Hypercholesterolemia
• Acquired Hypercholesterolemia

Hypercholesterolemia Treatment Market, By Treatment Type:

• Statins
• PCSK9 Inhibitors
• Ezetimibe
• Bile Acid Sequestrants
• Niacin
• Bempedoic Acid
• Others

Hypercholesterolemia Treatment Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centres
• Others

Hypercholesterolemia Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hypercholesterolemia Treatment Market.

Available Customizations:

Global Hypercholesterolemia Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hypercholesterolemia Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Genetic Hypercholesterolemia, Acquired Hypercholesterolemia)
  • 5.2.2. By Treatment Type (Statins, PCSK9 Inhibitors, Ezetimibe, Bile Acid Sequestrants, Niacin, Bempedoic Acid, Others)
  • 5.2.3. By End User (Hospitals, Specialty Cardiac Centres, Others)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Hypercholesterolemia Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Treatment Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Hypercholesterolemia Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Treatment Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Mexico Hypercholesterolemia Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Treatment Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Canada Hypercholesterolemia Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Treatment Type
      • 6.3.3.2.3. By End User

7. Europe Hypercholesterolemia Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Treatment Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Hypercholesterolemia Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Treatment Type
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Hypercholesterolemia Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Treatment Type
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Hypercholesterolemia Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Treatment Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Hypercholesterolemia Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Treatment Type
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Hypercholesterolemia Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Treatment Type
      • 7.3.5.2.3. By End User

8. Asia-Pacific Hypercholesterolemia Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Treatment Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Hypercholesterolemia Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Treatment Type
      • 8.3.1.2.3. By End User
  • 8.3.2. India Hypercholesterolemia Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Treatment Type
      • 8.3.2.2.3. By End User
  • 8.3.3. South Korea Hypercholesterolemia Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Treatment Type
      • 8.3.3.2.3. By End User
  • 8.3.4. Japan Hypercholesterolemia Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Treatment Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Hypercholesterolemia Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Treatment Type
      • 8.3.5.2.3. By End User

9. South America Hypercholesterolemia Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Treatment Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Hypercholesterolemia Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Treatment Type
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Hypercholesterolemia Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Treatment Type
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Hypercholesterolemia Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Treatment Type
      • 9.3.3.2.3. By End User

10. Middle East and Africa Hypercholesterolemia Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Treatment Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Hypercholesterolemia Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Treatment Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Hypercholesterolemia Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Treatment Type
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Hypercholesterolemia Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Treatment Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Amgen Inc
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Amryt Pharma plc
• 15.3. AstraZeneca Plc.
• 15.4. Regeneron Pharmaceuticals, Inc.
• 15.5. Novartis Pharmaceuticals Corporation
• 15.6. Teva Pharmaceutical Industries Ltd.
• 15.7. Cipher Pharmaceuticals Inc.
• 15.8. Pfizer Inc.
• 15.9. Merck & Co., Inc.
• 15.10. Sun Pharmaceutical Industries Limited

16. Strategic Recommendations

17. About Us & Disclaimer